Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition

Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas.

According to Lantern Pharma, the ODD designation applies in the United States under the FDA’s orphan drug program. The program supports the development of treatments for diseases affecting fewer than 200,000 people. This orphan drug status for LP-284 is the third such designation for this molecule; others are for mantle cell lymphoma (MCL) in January 2023 and high-grade B-cell lymphoma (HGBL) in November 2023. It is also the sixth overall orphan designation awarded to Lantern Pharma’s clinical pipeline.

In a different update, on January 12, Lantern Pharma established an Artificial Intelligence Center of Excellence and Advanced Agentic Labs in Bengaluru, India. The goal, said the company, is to industrialize and scale its proprietary RADR AI platform for global biopharma use.

The company plans the Bengaluru facility to act as a global scale-up hub for RADR. It will use it as the base for expanding computational capacity, large-scale data engineering, and development of machine learning-ready disease models. This platform will be integrated “more deeply” with pharmaceutical and academic partners worldwide, the company stated.

The RADR platform currently integrates hundreds of billions of oncology-focused data points, sophisticated machine learning algorithms, and curated disease models. All of these come together to create a system that identifies biomarkers, predicts drug response, and designs optimized clinical strategies.

Lantern Pharma, Inc. (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company that leverages artificial intelligence, machine learning, and genomics to accelerate oncology drug discovery and development. Its proprietary RADR AI platform analyzes billions of data points to identify biomarkers, predict drug responses, and optimize clinical trial design.

While we acknowledge the potential of LTRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Affordable Tech Stocks to Buy Right Now and 10 Best Affordable Long Term Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.